Revumenib + Placebo + Intensive Chemotherapy Regimen
Phase 3Recruiting 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemias
Conditions
Acute Myeloid Leukemias
Trial Timeline
Nov 25, 2025 → Jan 1, 2031
NCT ID
NCT07211958About Revumenib + Placebo + Intensive Chemotherapy Regimen
Revumenib + Placebo + Intensive Chemotherapy Regimen is a phase 3 stage product being developed by Syndax Pharmaceuticals for Acute Myeloid Leukemias. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07211958. Target conditions include Acute Myeloid Leukemias.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07211958 | Phase 3 | Recruiting |
Competing Products
20 competing products in Acute Myeloid Leukemias